ImmunityBio, Inc.(IBRX) Stock Research - Grey Stern Research
Loading...

ImmunityBio, Inc. (IBRX) Stock Analysis

$5.28 (-3.03%)

IBRX Financial Performance


Use the table below to view ImmunityBio, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $5.20 -
52 Week Low $2.67 -
52 Week High $10.53 -
Market Cap $3.6 Billion 6/17
Gross Margin -100% 15/17
Profit Margin -100% 12/17
EBITDA margin -9487% 17/17
Q1 - 2024 Revenue $1.0 Million 10/17
Q1 - 2024 Earnings -$134.6 Million 14/17
Q1 - 2024 Free Cash Flow $0 Million 17/17
Trailing 4 Quarters Revenue $1.3 Million 10/17
Trailing 4 Quarters Earnings -$597.6 Million 16/17
Quarterly Earnings Growth 2% 9/17
Annual Earnings Growth -1% 11/17
Quarterly Revenue Growth 2454% 2/17
Annual Revenue Growth 17% 6/17
Cash On Hand $130.1 Million 7/17
Short Term Debt $6.3 Million 6/17
Long Term Debt $956.3 Million 1/17

ImmunityBio, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare ImmunityBio, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/17
PS 2769.09 1/17
PB 0.00 14/17
PC 27.84 5/17
Liabilities to Equity 0.00 16/17
ROA -1.35 17/17
ROE 0.86 2/17
Current Ratio 0.39 17/17
Quick Ratio 0.19 16/17
Long Term Debt to Equity -1.37 17/17
Debt to Equity -1.43 16/17
Burn Rate 0.75 11/17
Cash to Cap 0.04 12/17
CCR 17/17
EV to EBITDA -45.21 15/17
EV to Revenue 3433.35 1/17

Company Details

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

CEO: Dr. Patrick Soon-Shiong F.A.C.S., M.Sc., FRCS (C), M.D., FACS

Website: https://immunitybio.com

Address: 2040 E MARIPOSA AVENUE El Segundo, CA

Exchange: NASDAQ Global Select

Industry: Biotechnology

ImmunityBio, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to ImmunityBio, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Viking Therapeutics, Inc. VKTX $7.2 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
TG Therapeutics, Inc. TGTX $4.0 Billion
Madrigal Pharmaceuticals, Inc. MDGL $7.4 Billion
Lexicon Pharmaceuticals, Inc. LXRX $430.2 Million
BioLineRx Ltd. BLRX $38.4 Million
Ardelyx, Inc. ARDX $1.4 Billion
Krystal Biotech, Inc. KRYS $5.0 Billion
Seres Therapeutics, Inc. MCRB $138.2 Million
aTyr Pharma, Inc. LIFE $131.1 Million
PDS Biotechnology Corporation PDSB $119.5 Million
X4 Pharmaceuticals, Inc. XFOR $93.7 Million
Vir Biotechnology, Inc. VIR $1.3 Billion
CureVac N.V. CVAC $657.2 Million
Elevation Oncology, Inc. ELEV $33.1 Million
eFFECTOR Therapeutics, Inc. EFTR $1,411
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
IBRX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 1.0 Million -$134.6 Million
Q1 2024 $ 40,000 -$134.1 Million
Q4 2023 $ 139,000 -$233.4 Million
Q3 2023 $ 82,000 -$95.6 Million
Q2 2023 $ 41,000 -$137.9 Million
Q1 2023 $ 360,000 -$151.2 Million
Q4 2022 $ 73,000 -$108.3 Million
Q3 2022 $ 118,000 -$110.9 Million

View All

IBRX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $130.1 Million $444.3 Million $999.0 Million -$697.4 Million
Q1 2024 $133.0 Million $400.7 Million $895.4 Million -$691.0 Million
Q4 2023 $265.5 Million $504.5 Million $883.7 Million -$585.9 Million
Q3 2023 $178.0 Million $432.4 Million $717.3 Million -$410.6 Million
Q2 2023 $43.5 Million $291.2 Million $819.2 Million -$642.1 Million
Q1 2023 $88.5 Million $343.4 Million $766.3 Million -$529.0 Million
Q4 2022 $104.6 Million $362.4 Million $723.8 Million -$447.3 Million
Q3 2022 $104.2 Million $352.9 Million $712.0 Million -$429.1 Million

View All

IBRX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 -$108.2 Million -$1.3 Million -$132.4 Million
Q4 2023 -$123.2 Million -$8.0 Million $87.5 Million
Q3 2023 -$93.1 Million -$5.7 Million $134.5 Million
Q2 2023 -$88.3 Million -$8.5 Million -$45.0 Million
Q1 2023 -$92.7 Million -$8.4 Million -$16.2 Million
Q4 2022 -$109.7 Million -$18.9 Million $480,000
Q3 2022 -$75.3 Million $5.3 Million $42.3 Million
Q2 2022 -$86.0 Million $5.3 Million $25.7 Million

View All